Susan Hasty, Publisher
Table of Contents . . . November 26th, 2002
Non-Subscriber - Summaries OnlyRelated Areas: Other Issues in Cancer Weekly | Other Publications
Kidney Cancer - Combination of cytotoxic and antiangiogenic agents diminish renal carcinoma
Melanoma - Research report shows new approach to replacing immune cells to shrink tumors
Cancer Therapy - AntiHIV agent active against malignant cells
Cancer Therapy - Tailor-made cancer drugs: Wave of the future?
Cancer Vaccine - Method to transduce leukemia B cells developed
Hepatocellular Carcinoma - Antisense nucleotides keep cancer cell proliferation in check
Leukemia - UCSD cancer researchers develop new antileukemia strategy
Prostate Cancer - COX-2 a factor in prostate cancer pathogenesis
Adverse Drug Events - Pharmaceutical company reports 39 cancer drug deaths in Japan
Antibody Therapy - HuMax-CD20 program targets lymphomas and autoimmune diseases
Brain Cancer - Novel carmustine formulation receives approval for clinical trial in Britain
Breast Cancer - Metastatic breast cancer vaccine trial to continue
Breast Cancer - Study shows Navelbine boosts Herceptin response without increasing side effects
Cancer Imaging - Novel tracer selects for proangiogenic protein in tumors
Cancer Pain - Radiofrequency ablation successfully treats bone pain
Cancer Prevention - Do certain foods trigger the body's cancer-fighting enzymes?
Cancer Therapies - Clinical trials of antibody underway
Cancer Therapies - Global testing contract signed supporting monoclonal antibody trials
Cancer Therapies - Unlabeled CEA antibody inhibits human tumor growth, enhances drug effects
Cancer Therapy - Bacterial protein kills tumors in mice
Cancer Therapy - Combination of IRESSA and radiation antagonizes tumor vessel growth
Cancer Therapy - Forced overexpression of enzyme inhibitor immobilizes tumor angiogenesis
Cancer Therapy - Roche and Kosan to develop and commercialize Epothilone D
Cancer Vaccine - Regulatory T cells may have a role in poor immune response against tumor antigens
Colon Cancer - Findings support benefits of women having screening colonoscopy at 50
Colon Cancer - USC consortium receives $15 million NCI grant to determine causes
Diagnostics - Antibody test shows 100% sensitivity, specificity in ruling in or out cancer
Drug-induced Toxicity - OGS and FDA to evaluate protein markers predictive of drug toxicity
Financing - Photogen announces revised $9 million financing
Gastric Cancer - First findings presented from phase II pemtumomab trial
Genetic Testing - Nanosphere wins grants for colorectal cancer and hypercoagulation genetic tests
Glioma Therapy - Radiotherapy enhances effect of gene-deleted virus on brain tumors
Head and Neck Cancer - Full enrollment phase II clinical trial announced
Hepatitis C Virus - Virus activates a protein sometimes linked to onset of cancer
Hodgkin Disease - Advanced disease prognostic score useful for predicting stem cell transplant outcome
Immunology - Biotech company says its scientists have created new molecules
Leukemia - Combination clofarabine/cytarabine therapy trial underway
Lung Cancer - Large scale study of tumor marker begins in Germany
Lung Cancer - New class of drugs reduces metastatic tumors by 80% in animal models
Lymphoma - Discovery may lead researchers to genetic mutations causing the cancer
Multiple Myeloma - Alternative to chemotherapy effective for newly diagnosed disease
Oncologic Pain - Radiofrequency ablation technology cleared for relief of bone tumor pain
Ovarian Cancer - Study finds survival prolonged with Taxol + cisplatin
Squamous Cell Carcinoma - Onyx regains all rights to virus platform and initiates repartnering efforts
Stem Cell Transplantation - Low-dose post-transplant interleukin-2 improves myeloid recovery
Tumor Blood Vessels - New vascular targeting agents win patent
Vaccine Development - Collaboration extended on therapeutic vaccines for three oncogenic viruses
Vaccine Development - Prostate cancer vaccine on track for phase III clinical trials
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.